Literature DB >> 15645308

The growth hormone-insulin like growth factor axis revisited: lessons from IGF-1 and IGF-1 receptor gene targeting.

Shoshana Yakar1, Hyunsook Kim, Hong Zhao, Yuka Toyoshima, Patricia Pennisi, Oksana Gavrilova, Derek Leroith.   

Abstract

We have created a liver-specific igf1 gene-deletion mouse model (LID) with markedly reduced circulating IGF-I levels. They demonstrate that while they have normal growth and development they develop insulin resistance secondary to the elevation of circulating growth hormone. When mated with an acid-labile subunit (ALS) gene-deleted mouse they also show osteopenia suggesting that circulating IGF-I levels play a significant role in bone formation. In a separate transgenic mouse we created a model of severe insulin resistance and type 2 diabetes by the overexpression of a dominant-negative IGF-I receptor in skeletal muscle. In this model we show that lipotoxicity plays a major role in the progression of the disease and is affected by treatment with a fibrate, which reverses the insulin resistance and diabetic state. These models are therefore very useful in studying human physiology and disease states.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15645308     DOI: 10.1007/s00467-004-1613-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

Review 1.  The somatomedin hypothesis: 2001.

Authors:  D Le Roith; C Bondy; S Yakar; J L Liu; A Butler
Journal:  Endocr Rev       Date:  2001-02       Impact factor: 19.871

2.  Somatomedin: proposed designation for sulphation factor.

Authors:  W H Daughaday; K Hall; M S Raben; W D Salmon; J L van den Brande; J J van Wyk
Journal:  Nature       Date:  1972-01-14       Impact factor: 49.962

3.  Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes.

Authors:  A M Fernández; J K Kim; S Yakar; J Dupont; C Hernandez-Sanchez; A L Castle; J Filmore; G I Shulman; D Le Roith
Journal:  Genes Dev       Date:  2001-08-01       Impact factor: 11.361

4.  Normal growth and development in the absence of hepatic insulin-like growth factor I.

Authors:  S Yakar; J L Liu; B Stannard; A Butler; D Accili; B Sauer; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

5.  Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity.

Authors:  S Yakar; J L Liu; A M Fernandez; Y Wu; A V Schally; J Frystyk; S D Chernausek; W Mejia; D Le Roith
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

6.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance.

Authors:  Martin Haluzik; Shoshana Yakar; Oksana Gavrilova; Jennifer Setser; Yves Boisclair; Derek LeRoith
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

8.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Authors:  Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

9.  Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

Authors:  Hyunsook Kim; Martin Haluzik; Zeenat Asghar; Daphne Yau; Jamie W Joseph; Ana M Fernandez; Marc L Reitman; Shoshana Yakar; Bethel Stannard; Lisa Heron-Milhavet; Michael B Wheeler; Derek LeRoith
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

10.  Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3).

Authors:  H Kato; T N Faria; B Stannard; C T Roberts; D LeRoith
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

  10 in total
  23 in total

1.  Genetic analysis of serum osteocalcin and bone mineral in multigenerational Afro-Caribbean families.

Authors:  A L Kuipers; C Gundberg; C M Kammerer; A S Dressen; C S Nestlerode; A L Patrick; V W Wheeler; C H Bunker; A B Newman; J M Zmuda
Journal:  Osteoporos Int       Date:  2011-09-21       Impact factor: 4.507

Review 2.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

3.  Essential role of Pten in body size determination and pancreatic beta-cell homeostasis in vivo.

Authors:  Kinh-Tung T Nguyen; Panteha Tajmir; Chia Hung Lin; Nicole Liadis; Xu-Dong Zhu; Mohammed Eweida; Gunce Tolasa-Karaman; Fang Cai; Rennian Wang; Tadahiro Kitamura; Denise D Belsham; Michael B Wheeler; Akira Suzuki; Tak W Mak; Minna Woo
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 4.  Lifelong consequences of brain injuries during development: From risk to resilience.

Authors:  Zachary M Weil; Kate Karelina
Journal:  Front Neuroendocrinol       Date:  2019-09-24       Impact factor: 8.606

5.  Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.

Authors:  V Gasco; G Beccuti; F Marotta; N Prencipe; M Maccario; J Janssen; A J van der Lely; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2011-05-31       Impact factor: 4.256

6.  Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.

Authors:  Yingjie Wu; Hui Sun; Jelena Basta-Pljakic; Luis Cardoso; Oran D Kennedy; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Mitchell B Schaffler; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

7.  Effects of low-dose parathyroid hormone on bone mass, turnover, and ectopic osteoinduction in a rat model for chronic alcohol abuse.

Authors:  U T Iwaniec; C H Trevisiol; G F Maddalozzo; C J Rosen; R T Turner
Journal:  Bone       Date:  2008-01-12       Impact factor: 4.398

8.  Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice.

Authors:  Yingjie Wu; Hui Sun; Shoshana Yakar; Derek LeRoith
Journal:  Endocrinology       Date:  2009-06-04       Impact factor: 4.736

9.  Effects of maternal global nutrient restriction on fetal baboon hepatic insulin-like growth factor system genes and gene products.

Authors:  Cun Li; Natalia E Schlabritz-Loutsevitch; Gene B Hubbard; Victor Han; Karen Nygard; Laura A Cox; Thomas J McDonald; Peter W Nathanielsz
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

10.  Crosstalk between the AMP-activated kinase and insulin signaling pathways rescues murine blastocyst cells from insulin resistance.

Authors:  Erica Louden; Maggie M Chi; Kelle H Moley
Journal:  Reproduction       Date:  2008-06-24       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.